• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Coimbatore, Aug. 11

Venus Remedies Ltd has successfully launched a fixed dose combination of Cephalosporin with amino glycoside under the brand name ‘Tobracef’ in domestic market for the first time. Tobracef is a God send for APE/Cystic Fibrosis patients being the only solution for the treatment of life threatening infections caused by P. Aeruginosa/MRSA in these patients. The company is targeting to penetrate the Rs 200-crore domestic market and is expected to build this brand as a segment leader within 2 years of its launch. There are approximately 50 patent applications in process in 50 countries across the globe for this product and the company is in talks for licensing of this product in US and other regulated markets.

– Our Bureau

More Stories on : Announcements | New Products & Services | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line